Tag: 180-day exclusivity
Paragraph IV Certifications: How Generic Drug Makers Legally Challenge Brand-Name Patents
Paragraph IV certifications let generic drug makers legally challenge brand-name patents before launch. This Hatch-Waxman Act tool drives down drug prices by enabling 180-day market exclusivity for the first challenger - but it comes with high legal risks and complex rules.
Detail